Give dogs more
healthy years
Join our STAY study to help dogs live longer, healthier lives.
and our drug
We’ve launched the STAY study — a double-blinded, placebo-controlled study recruiting 1,000 senior dogs in partnership with 70 veterinary clinics across the country. This is our final effectiveness study for LOY-002 to support our submission for FDA approval.
our study?
“Over the years, I’ve had seven pets who needed to be put down — it’s part of life. Mickey is my eighth companion.
We’ve been at this clinic since 2008. They take care of my animals. I trust them. I trust Dr. Ramirez, especially. This study felt like a win-win.”
By participating, you’re contributing to the development of innovative, safe, and effective medications to extend the lifespan of dogs and maintain their quality of life as they age.
Your dog will receive vet check-ups and study-related lab work at no cost to you for the duration of the study.
To be eligible your dog must be at least 10 years old and weigh 14 pounds or more.
You’ll need to commit to participating in a study that will span up to four years.
You’ll give your dog the flavored chewable study medication every day.
You’ll also need to complete brief surveys about your dog’s quality of life throughout the study, which can be completed at the vet clinic or at home on your smartphone, tablet, or computer.
Finally, you’ll need to transfer your dog’s primary care to the study clinic and bring your dog to the clinic for study visits — six visits in the first year and two visits a year for the remaining years.
Since the study is double-blinded and placebo-controlled, early access to the drug is not guaranteed as your dog has a 50% chance of receiving active drug or placebo.
This study will compare the lifespan, health, and quality of life in dogs taking the study drug against dogs that are given placebo tablets that do not contain the drug.
We hope that the dogs on the study drug will live longer and stay healthier — the study is designed to tell us in a controlled, unbiased way whether they do. As a participant in the study your dog may be given the study drug or may be on a placebo, but this information will remain blinded until after the study has ended.
After the study ends, the drug will be submitted to the FDA for approval as a prescription product.
All dogs in the STAY study must be 10 or older at the time of enrollment with documentation of age. These requirements are necessary to ensure the scientific integrity of our study, so we’re not able to make any exceptions.
For LOY-002, we have extensive data in over 400 dogs, including longitudinal studies of up to a year, and a pilot field study. We’ll be able to share this data as we get closer to launch.
If your dog does experience side effects from the drug, you’ll be supported with safety resources, including training on how to recognize side effects and access to a 24/7 hotline.
LOY-002 is not aimed at treating a specific disease. Therefore, if your dog is given the placebo in the study, they do not run any risks associated with being untreated. If your dog gets sick for any reason, you are free to treat your dog with normal veterinary care.
Loyal is an animal health biotech company based in San Francisco. We’re developing drugs that extend the healthy lifespan of dogs and help maintain their quality of life as they age. We’re partnering with veterinarians across the country to conduct our STAY study, the largest clinical study of its kind ever conducted.